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Two years after the publication of the 2013 guidelines for the management of arterial 
hypertension of the European Society of Hypertension (ESH) and the European Society of 
Cardiology (ESC) (1), the ESH and the European Union Geriatric Medicine Society 
(EUGMS) have created a common working group in order to examine the management of 
hypertensive subjects over 80 years old. The general term “Hypertension in the elderly” is not 
sufficiently accurate since it mixes “younger” old patients (60-70 years) with the oldest old. 
Our group believes that the management of hypertension in individuals aged 80 years and 
older should be specifically addressed. Although arbitrary, this cut-off value identifies a 
population which is expanding faster than any other age group with a 50% increase  of life 
expectancy during the past 50 years (2,3); furthermore, the incidence and prevalence of co-
morbidities, frailty and loss of autonomy greatly increases after the age of 80 years (4); 
finally, although there is limited evidence regarding the management of hypertension in this 
age group, the latest clinical studies indicate that in these patients treatment may not be the 
same as in patients in the lower age strata. 
Aim of this Working Group was to discuss more in-depth a number of treatment aspects of 
hypertensive patients aged 80 years or older, with special focus on the difficulties and 
uncertainties posed by very old frail individuals. We focused, in particular, on the following 
points of the 2013 ESH/ESC guidelines 
• Benefits of treatment  
• Blood pressure (BP) thresholds and targets 
• The choice of treatment 
 
1- Benefits of treatment 
The 2013 ESH/ESC guidelines (1), reported the results of the HYpertension in the Very 
Elderly double blind Trial (HYVET). This showed that in hypertensive patients aged 80 years 
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or more the administration of the thiazide-like diuretic indapamide supplemented, if 
necessary, by the ACE inhibitor perindopril led to a significant reduction in the risk of major 
cardiovascular events and all cause death compared to placebo (2). From this, the guidelines 
concluded that there is evidence that antihypertensive treatment is beneficial in octogenarians 
in whom BP is elevated, and that therefore BP lowering interventions can be strongly 
recommended within this age range. However, both the ESH/ESC guidelines (1) and other 
publications (5-8) also point out limitations in the demonstration that treatment is beneficial in 
octogenarians and this need to be addressed. First, the HYVET is thus far the only 
randomized clinical trial that has addressed this important issue, making confirmation by a 
second trial highly desirable. Second, the age of the HYVET patients was for the most part 
closer to 80 years (73% in the 80-84 and 22% in the 85-89 range), leaving the effect of 
treatment in patients close to or above 90 years of age largely unexplored. Third, because the 
trial was prematurely interrupted by the Safety Monitoring Board (due to the evidence of 
protective effect of BP reduction in the treated group) the follow-up was rather short (median 
1.8 years). Despite the observation that in the HYVET patients the rate of events remained 
lower in the originally treated group one year after the trial termination (9), this requires the 
duration of benefit to be determined. Finally, the 2013 ESH/ESC guidelines state that ‘the 
HYVET deliberately recruited patients in good physical and mental conditions and excluded 
ill and frail individuals, who are common among octogenarians, and also excluded patients 
with clinically relevant orthostatic hypotension’ (1), thereby emphasizing probably the most 
important limitation of the available information, i.e. leaving out of consideration the 
influence of patients’ general health, concomitant medication and frailty on the decision about 
antihypertensive treatment implementation. 
Post hoc analysis of the HYVET trial did not find a relationship between the benefit of 
antihypertensive treatment and patients’ frailty (10). This is reassuring for community-
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dwelling older hypertensives but it is worth remembering that the HYVET did not include 
very frail patients and that patients with multiple morbidities and clinically significant 
cognitive impairment were also excluded. Indeed, both recent observational studies and 
registries show an important influence of the frailty status on the relationship between BP and 
outcomes, especially in treated hypertensives. This can be exemplified by studies that show 
the association between BP and mortality to vary according to the walking speed (11), 
cognitive function, assessed with the mini mental state examination (MMSE) and disability, 
measured using the activity of daily living (ADL) (12). Indeed, Odden et al (11) showed that, 
systolic BP in faster walkers was positively correlated with mortality, while no relationship 
between BP and mortality was observed among slower walkers. Moreover, in patients unable 
to complete the walk test BP was negatively associated with the risk of death (6). In the Milan 
Geriatrics study (12), higher systolic BP values were related to lower mortality among 
individuals aged 75 years or older who had an impaired MMSE (< 25 points) or ADL (<6 
points). Also, the Predictive Value of Blood Pressure and Arterial Stiffness in 
Institutionalized Very Aged Population (PARTAGE) study has shown that what applies to 
middle-aged persons does not necessarily apply to old (≥ 80 years) nursing home residents 
(13-15), i.e. the frailest oldest patients. Actually, in this very old frail population, values of BP 
recorded with clinical standard procedures were very similar to those obtained with multiple 
3-day morning and evening measurements » (13) and the negative relationship between the 
main endpoint of the study (total mortality and major CV events) and SBP was observed with 
BP measured by a clinician, or self-measured (14).  Interestingly, in this study the highest 
mortality rate was observed in patients with systolic BP less than 130 mmHg, who were 
treated with two or more antihypertensive drugs, at variance from what was seen in those 
treated with one antihypertensive agent or not receiving any antihypertensive drug at all (15). 
Likewise, Mossello et al (16) found a more pronounced cognitive decline in treated old 
 5
hypertensive patients suffering from mild cognitive impairment or dementia in whom systolic 
BP was low (< 128 mmHg). Such an effect was not observed in subjects with low systolic BP 
but without antihypertensive treatment. 
 It is important to remember that both low BP and orthostatic hypotension are associated with 
syncope, falls and related injuries and fractures (17-19). Therefore, both the benefits 
(including preserving autonomy) and the risks of antihypertensive therapy should be 
considered before starting treatment in the very frail older population. This population is the 
one at the highest risk of hypertension-related cardiovascular events, but also of hypotension-
related events (19-21). Hypotension-related events are likely to be more common in real life 
than in clinical trials in which treatment is delivered by expert physicians and patients are 
followed closely. In a recent analysis of a large real-life database very old individuals showed 
a significant increase in hospitalizations for hip fracture over the 30 days after initiation of 
antihypertensive drug treatment (22). This has been previously observed in patients with a 
mean age of 80 years (26% between 86 and 100) over the 45 days after antihypertensive 
treatment initiation (23). 
 
2- BP thresholds and targets 
Because in the HYVET, patients were recruited if their entry systolic BP was ≥ 160 mmHg, 
this is the systolic BP value recommended by the 2013 ESH/ESC guidelines at which drug 
treatment in octogenarians should be started (1). The threshold for treatment has been set at a 
lower systolic BP level (≥ 150 mmHg) in the US 2014 guidelines (5) but because 
octogenarians with entry systolic BP values < 160 mmHg have never been studied in 
randomized clinical trials nor shown to have beneficial effects of BP lowering interventions in 
subgroup data from trials addressing a larger age range, this does not appear to be based on 
solid evidence. It remains thus unsubstantiated whether in this very old patient category grade 
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1 hypertension, i.e. a systolic BP between 140 and 159 mmHg, might benefit from 
antihypertensive drugs. 
Evidence on the BP goals for treatment in octogenarians is also limited. Both the 2013 
ESH/ESC (1) and the US guidelines (5) recommend adopting the goal set by the HYVET, i.e. 
< 150 mmHg systolic BP but neither addresses the question of the systolic BP value below 
which the treatment may interfere with patients’ safety. This is a critical issue because, as 
mentioned above, i) observational studies have repeatedly shown that in the very old 
population low BP values are associated with an increased morbidity and mortality ii), 
somewhat statistically underpowered, randomized Japanese trials have not found clear 
benefits of systolic BP reductions below 140 mmHg (24, 25) and iii) a systolic BP reduction 
to <120, 130 or even 140 mmHg may be associated with an increased risk of negative 
outcomes, i.e. a J curve phenomenon that appeared to be especially evident in frail 
individuals. Although the possibility of reverse causality (i.e. greater initial risk as the cause 
of an excessive BP fall and increased outcomes) cannot be excluded, a pathophysiologically 
founded hypothesis is that in frail very old subjects an impairment of the mechanisms 
preserving perfusion might critically decrease blood flow to vital organs (heart, brain, kidney) 
(21). This is at variance from healthier old individuals in whom no clear negative influence of 
blood pressure decrease on vital organ perfusion and associated complications has been 
reported (26, 27). Therefore, the following multiple questions still remain open. Do frail very 
old hypertensives get benefits from antihypertensive treatment? Is the benefit similar or 
different in non-frail and frail individuals? Should the BP threshold at which to start treatment 
be higher as recently recommended by guidelines? Which are the BP targets that maximize 
protection in frail very old patients, without posing a risk to their safety? 
The recently published Systolic Blood Pressure Intervention Trial (SPRINT) (28) shows that 
among patients at high cardiovascular risk and already using antihypertensive drugs targeting 
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a systolic BP of 120 mmHg resulted in lower incidence of major cardiovascular events and 
death from any cause compared to patients targeting a systolic BP of 140 mmHg; this result 
was also statistically significant in the subgroup (28% of all) of patients more than 75 years 
old. However, in the SPRINT the number of patients aged 80 years or older has not been 
reported and may be substantially lower than the 28% (2600) patients aged 75 years or older.. 
Furthermore, interpretation of several aspects of the SPRINT data (lack of beneficial effect on 
stroke, masking effect of diuretics on signs and symptoms of more than three drug heart 
failure, blood pressure measuring approach, etc) are still under discussion (29,30). Finally, 
and more importantly, in patients with advanced frailty, cognitive decline, loss of autonomy 
and living in nursing home were excluded from the trial. Exclusion from trial extended to 
patients with decompensated heart failure, history of stroke and diabetes, i.e. conditions very 
commonly associated with hypertension in very aged individuals in whom they represent a 
common cause of death. This is a crucial issue also because in SPRINT, the aggressively 
treated group showed a substantial increase of hypotension, syncope, electrolyte abnormalities 
and renal failure, i.e. adverse reactions that are likely to be magnified in very old patients, 
even more so if frail. Thus, application of the SPRINT results in this population cannot be 
done unconditionally, also considering that other studies including frail people have not 
obtained similar results.  While potentially useful to robust old hypertensives, these results 
may have a limited transferability to frail, very old patients in whom the treatment strategies 
and the treatment goals should be largely driven by their functional status and comorbidities.  
3- Choice of treatment 
Based on trials performed in patients aged 60 years or more both the 2013 ESH/ESC 
(1) guidelines and the US guidelines (2) recommend the antihypertensive treatment to be 
implemented in old hypertensive subjects to use the same drug classes that are recommended 
for younger patients, i.e. diuretics, angiotensin receptor antagonists, ACE inhibitors and 
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calcium channel blockers, with an extension to beta-blockers in the ESH/ESC guidelines (1). 
Based on large meta-analyses they also consider the above 5 classes similarly protective in 
old hypertensive individuals, although indicating diuretics and calcium channel blockers as 
the preferred choice in isolated systolic hypertension given the preferential use of these two 
drugs in trials on this condition. Neither the European nor the United States guidelines 
mention any difference in the type of treatment in hypertensive patients aged 80 years or more 
compared to patients below 80 years. In the HYVET the drugs employed were the thiazide-
like diuretic indapamide complemented by perindopril in about 70% of the patients, 
suggesting a possible preference for a treatment based on a diuretic-ACE inhibitor 
combination. However, in a pre-specified secondary analysis of a Japanese study (31) on 
hypertensive patients aged 75-84 years, those receiving an angiotensin receptor 
antagonist/calcium channel blocker combination showed a reduction in the risk of stroke 
compared to patients receiving an angiotensin receptor antagonist/diuretic combination. Given 
the evidence that the benefit of treatment largely depends on BP lowering per se (32), i.e. 
regardless how it is obtained, the opinion of this Working Group is that in principle the large 
number of antihypertensive drug classes recommended for younger age strata are suitable for 
use also in the oldest-old individuals. Except when required for specific clinical conditions 
(e.g. angina pectoris, previous myocardial infarction and heart failure), use of beta-blockers in 
these very old hypertensive individuals remains controversial, however (33,34). 
In the 2013 ESH/ESC guidelines (1) the suggestion is made to consider initiation of 
antihypertensive treatment with a 2-drug combination if cardiovascular risk is high, with no 
distinction between younger and older patients. However, in octogenarians, initial 
administration of two antihypertensive drugs, even when administered at low doses, may put 
subjects at an unwarranted risk of hypotension, given that homeostatic mechanisms that 
maintain BP against gravity and other challenges undergo a progressive impairment as age 
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advances (35). Furthermore, increasing the number of the prescribed drugs may increase the 
probability of adverse drug, drug-drug and drug-disease reactions and interactions in patients 
in whom polypharmacy is extremely common due to the frequent concomitance of both 
cardiovascular and non-cardiovascular diseases (36,37). Finally, an increased number of 
prescribed drugs is known to have a negative effect on adherence to treatment, an especially 
serious problem in very old patients in whom adherence (and errors in taking the prescribed 
medicines) may be adversely affected by cognitive dysfunction and dementia (38). 
Combination of two antihypertensive drugs should be considered if monotherapy fails to 
control BP, but only if consideration of the potential protective effect of BP reduction versus 
the risk of hypotension and other adverse effects makes a benefit likely. As already mentioned 
in the 2013 ESH/ESC (1) and other guidelines (8), antihypertensive treatment in 
octogenarians should in general not exceed 3 different medications, unless BP remains 
severely uncontrolled, or patients become 80 under an earlier initiated more than three drug 
regime, but still well-tolerated, treatment. Under these circumstances, however, patients’ 
follow-up should be intensified because a large body of evidence shows that drug-to-drug 
interactions and other iatrogenic problems dramatically increase with an increase in the 
number of administered drugs and more so in frail patients (39) 
 
Suggestions of the Working Group for the management of hypertension in 
octogenarians. 
 Based on the above comments, we propose the following: 
a- Treatment initiation: The 2013 ESH/ESC guidelines state that in individuals aged 80 
years or older with an initial systolic BP ≥160 mmHg, systolic BP should be reduced by drug 
treatment provided that patients are in good physical and mental conditions. We believe that 
this recommendation should be accompanied by 1) a more precise definition of the meaning 
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of the term “good physical and mental conditions” and 2) an indication of how physical 
conditions, mental conditions and the frailty status can be assessed. 
 A rapid (<10 minutes) assessment of frailty is feasible. The most frequently employed is the 
Fried frailty phenotype (40) in which frailty is defined by the presence of at least 3 of the 
following: weight loss, exhaustion, weakness, decreased gait speed, and diminished physical 
activity. Other scales used in different countries (41-43) may also be referred to. 
The ESH/ESC guidelines also state, that “continuation of a well tolerated antihypertensive 
treatment should be considered when a treated individual becomes octogenarian”. This is a 
reasonable recommendation, but we suggest that in this case physicians are advised to 
monitor the frailty status in order to detect when a change in treatment strategy may be 
needed. 
b- Treatment goals: The 2013 ESH/ESC guidelines recommend treatment to lower systolic 
BP to < 150 mmHg in octogenarians in good physical and mental conditions We believe that 
this might be usefully complemented by mentioning that, while keeping <150 mmHg systolic 
BP as the evidence-based target, for safety reasons antihypertensive drugs should be reduced 
or even stopped if systolic BP is lowered to <130 mmHg, thus keeping the 150 to 130 mmHg 
on-treatment systolic BP values as a safety range. Self-assessment of BP at home and if 
necessary 24 h ambulatory BP measurements can contribute to identify treated patients with 
too low BP levels. Some consideration should also be given to the assessment of subclinical 
organ damage in particular, systolic and diastolic dysfunction as well as arterial stiffness. 
However the question is raised, concerning the prognostic significance of these parameters in 
older hypertensives, and whether their improvement would actually translate into an 
improvement in mortality in the elderly. (44). It should be emphasized that nearly all 
guidelines on BP targets refer to office BP values because no outcome trial has addressed the 
optimal out-of-office BP target in older or younger hypertensive patient strata. To date, what 
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has been established is that 1) office BP is higher than 24-h mean or home BP  (45) and 2) 
this discrepancy decreases progressively as office BP decreases. This suggests that these 
values do not differ substantially in individuals with office BP controlled (46), a possibility, 
however, that needs to be tested by randomized trials.  
 
c- Choice of antihypertensive drugs: The 2013 ESH/ESC guidelines (1) recommend all five 
major antihypertensive drug classes (with a preference for diuretics and calcium channel 
blockers in isolated systolic hypertension) for use in old hypertensive subjects, with no 
distinction between those above or below 80 years of age. We suggest that a distinction 
should be made and that, based on the HYVET, in octogenarians, ACE inhibitors and 
thiazide-like diuretics should be positioned at the same level as calcium channel blockers. The 
working group thinks that despite the age-related high cardiovascular risk, initial high dose or 
combination treatment should not be encouraged, and that combination treatment should only 
be considered after failure of initial low dose therapy.  
 
d- Frail very old patients (people living in nursing homes or needing assistance on a 
daily basis for their basic activities): The 2013 ESH/ESC guidelines state that “ in frail 
older patients, it is recommended to leave decisions on antihypertensive therapy to the 
treating physician, and base them on monitoring of the clinical effects of treatment” We 
suggest that in these patients therapeutic decisions should be preceded by 1) accurate 
information on their functional capacity, cognitive status. Although notoriously difficult, an 
estimate of patient’s prognosis should also be attempted; 2) attention to multiple drug 
administration so common in this age stratum; 3) stratification of the frailty status by one of 
the available rapid methods; and 4) identification and correction of factors that predispose to 
an excessive BP reduction, orthostatic hypotension, and other hypotensive episodes, such as 
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concomitant treatments, malnutrition and dehydration. The decision of the practicing 
physician to start treatment in a frail very old patient should be especially cautious (low drug 
doses and monotherapy) and to check patient status on a frequent basis  
It is obvious that the recommendations of our group pertain mainly to very old people (i.e. 80 
year or over) with frailty. However, we believe that an individual in his late sixties or early 
seventies who expresses the condition of frailty - and in whom at that moment a difference 
between the calendar and the biological age becomes apparent- should be approached in a 
similar way. Since prevalence of frailty dramatically increases with increasing age (47), the 
latter situation however would take place in few cases. For this reasons, a systematic 
screening for frailty, which we propose for very old people, might take place in their younger 
counterparts only when a clinical and functional problems become imminent. 
Finally, we would like to point out that research based on registries, administrative databases 
but also interventional controlled trials should be favoured to assess the benefits/risks ratio of 
multi-drug antihypertensive treatment in the growing population of very old frail patients.  
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